Serum TAM Receptor Tyrosine Kinase Ligands in Acute Pancreatitis

NCT07023055 | Completed

• 1 other identifier: 2024-SR-958
• Study Type: observational
• Target: 896
• Locations: 1 country
• Sites: 1

Brief Summary

AXL and MERTK are homologous members of the TAM (TYRO3, AXL, MERTK) receptor tyrosine kinase family. They function as critical regulators of antiviral immunity, autoimmune responses, and tumor microenvironment modulation through their bridging ligands, GAS6 (Growth Arrest-Specific 6) and PROS1 (Protein S). These receptors serve as damage sensors that negatively regulate inflammation, promote tissue repair/remodeling, and modulate fibrotic processes in chronic inflammatory conditions. Building upon our previous work demonstrating the pivotal role of the AXL/MERTK signaling axis in AP pathogenesis - particularly in pancreatic necrosis regulation, this clinical study seeks to evaluate the prognostic value of the TAM receptor ligands GAS6 and PROS1 as biomarkers for predicting AP severity.

Conditions

Acute Pancreatic Necrosis; Acute Pancreatitis (AP)

Outcome Measures

Primary Outcomes (1)

• Proportion of Participants with Severe Acute Pancreatitis

  AP severity was classified as mild (MAP), moderately severe (MSAP), or severe (SAP) according to the revised Atlanta classification.

  2 days

Secondary Outcomes (1)

• Incidence Rate of Persistent Organ Failure (≥48 Hours) in Acute Pancreatitis

  2 days

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Diagnosed with AP based on at least two of the following criteria (1) acute onset of upper abdominal pain; (2) more than three times the upper limit of the normal range of serum lipase or amylase levels; and (3) typical radiological findings of AP on computed tomography (CT), magnetic resonance imaging, or ultrasonography.

You may qualify if:

• Age 18-80 years.
• Patients diagnosed with acute pancreatitis in outpatient/emergency departments, inpatient wards, or health examination centers starting from 2024.

You may not qualify if:

• Patients with chronic pancreatitis or pancreatic cancer.
• Pregnant or lactating women.
• Patients who did not provide informed consent.
• Patients with severe organic diseases, such as malignant tumors, acute myocardial infarction, or large-scale cerebral infarction.

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead
• The first affiliated Hospital of Nanjing Medical University, Jiangsu Province: collaborator

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

Pancreatitis

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 8, 2025
• First Posted: June 15, 2025
• Study Start: January 1, 2024
• Primary Completion: March 1, 2025
• Study Completion: March 1, 2025
• Last Updated: June 22, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)